ArticleMolecular biology reports2026
LAMB1 accelerates esophageal squamous cell carcinoma by triggering JAK2/STAT3 signaling.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCharacterized by a high death rate and negative clinical results, esophageal squamous cell carcinoma (ESCC) is a malignant tumor of the digestive tract. Laminin subunit beta 1 (LAMB1), a principal glycoprotein in the extracellular matrix, contributes to the progression of various malignancies. However, the role and regulatory mechanisms of LAMB1 in ESCC are remain unclear. The objective of this study is to examine the expression profile, biological effects, and mechanisms underlying LAMB1 in ESCC. METHODS AND
resultsBioinformatic screening based on TCGA datasets and ECM-related gene sets identified LAMB1 as a prognosis-associated candidate gene. Through quantitative PCR (qPCR), Western blot and immunohistochemistry, we found that LAMB1 expression was increased in ESCC tissues and cell lines. Functional assays showed that LAMB1 overexpression promoted ESCC cell proliferation, migration and invasion, while LAMB1 knockdown suppressed these malignant phenotypes. Mechanistically, LAMB1 activated JAK2/STAT3 signaling by enhancing protein phosphorylation. Both JAK1/2 inhibitor (ruxolitinib) treatment and STAT3 silencing efficiently abrogated LAMB1-driven malignant phenotypes. In vivo xenograft experiments further confirmed that LAMB1 knockdown inhibited tumor growth and inhibited the activation of JAK2/STAT3 pathway.
conclusionsLAMB1 facilitates ESCC malignant progression via activating the JAK2/STAT3 pathway. LAMB1 may serve as a promising prognostic biomarker and therapeutic target for ESCC.
Indexed as
Identifiers
42878970What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.